This segment focuses on the research, development, and commercialization of small molecule therapeutics for various oncology indications. Key activities include the discovery and development of CDK4/6 inhibitors like trilaciclib and lerociclib, as well as the commercialization of COSELA. Research and development efforts involve preclinical studies, clinical trials across multiple phases, and regulatory submissions for FDA approval. Technologies employed include advanced medicinal chemistry, cell-based assays, and clinical trial management systems. The primary therapeutic areas are lung cancer, breast cancer, and colorectal cancer, with potential expansion into other cancers. The goal is to improve patient outcomes by reducing chemotherapy-induced myelosuppression and improving overall survival. Market positioning is based on providing innovative therapies with unmet medical needs. Future opportunities include expanding the product pipeline and securing additional regulatory approvals. This segment involves collaborations with pharmaceutical companies and research institutions to accelerate drug development and market access.

This segment encompasses the commercialization of G1 Therapeutics' approved products, including COSELA. It involves sales, marketing, and distribution activities to ensure that the company's therapies reach patients and healthcare providers. The segment focuses on building relationships with oncologists, hospitals, and pharmacies to drive product adoption. Key activities include market access strategies, medical affairs, and patient support programs. Technologies used include CRM systems, data analytics for sales and marketing, and digital platforms for healthcare professional engagement. The primary therapeutic area is chemotherapy-induced myelosuppression, with a focus on improving patient outcomes and quality of life. Market positioning is based on providing innovative therapies with unmet medical needs. Future opportunities include expanding the sales force, launching new products, and expanding into new markets. This segment involves partnerships with distribution companies and healthcare providers to ensure product availability and patient access.